By Mill Chart
Last update: Mar 7, 2024
Discover CORCEPT THERAPEUTICS INC (NASDAQ:CORT), an undervalued growth gem identified by our stock screener. NASDAQ:CORT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability. What's more, it retains an appealing valuation. We'll break it down further.
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:CORT has achieved a 7 out of 10:
ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:CORT was assigned a score of 6 for valuation:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:CORT, the assigned 9 for health provides valuable insights:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:CORT, the assigned 8 is a significant indicator of profitability:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Our latest full fundamental report of CORT contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (4/22/2024, 7:00:01 PM)
After market: 22.87 +0.57 (+2.56%)22.3
-0.65 (-2.83%)
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.
MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...